eli lilly glp-1 - Search News

News

Eli Lilly, GLP-1

CNN on MSN · 4d

Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that it helped people lower their weight by an average of 12% after 72 weeks.

CBS News on MSN · 3d

Eli Lilly weight loss pill shows promise in latest clinical trial, company says

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

USA TODAY on MSN · 2d

Will Eli Lilly’s new GLP-1 pill work as well as the shot? Here's what we know now

Eli Lilly’s GLP-1 pill helped some participants lose up to 15% body weight. But is it as effective as the injection? Here's what we know now.

2d

GLP-1 race heats up: Where Eli Lilly stands after weak trial data

Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...

2don MSN

Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

3d

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

3don MSN

Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

1d

Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

2d

Eli Lilly: Another Not-To-Miss Dip

Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results